|
|
|
|
 |
SAN DIEGO--- Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Senior Vice President, Regulatory Affairs and Quality Assurance |
| Companies mentioned in this article: |
|
Cadence Pharmaceuticals |
|
| 8/29/2008 @ 8:35 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) announced today the appointments of Todd Rich, M.D. to the company's board of directors and Malcolm Lloyd-Smith to the position of Senior Vice President, Regulatory Affairs and Quality Assurance. Mr. Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company for medical reasons.
"We are very pleased to welcome Dr. Rich to our board of directors," stated Cam Garner, Chairman of Cadence. "Todd brings to Cadence a wealth of clinical development, regulatory, and general management expertise, which will be invaluable as we continue to build a world class, hospital-focused biopharmaceutical company."
"Malcolm's extensive regulatory and quality assurance experience is a great asset to Cadence," added James Breitmeyer, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Cadence. "Malcolm will play a key role in helping us achieve our regulatory objectives for our two Phase III product candidates, Acetavance for the treatment of acute pain and fever, and Omigard for the prevention of catheter-related infections."
Dr. Rich is currently Vice President, Development Regulatory, Medical Information, Drug Safety, Quality and Compliance at Genentech, Inc. Dr. Rich joined Genentech in 1992 and has served in a variety of roles, including Vice President, Clinical and Commercial Regulatory Affairs and Senior Director, Product Development, where he was the Global Project Team Leader for Rituxan (rituximab). Previously, he was a Staff Physician at St. John's Hospital in Detroit, Michigan. Dr. Rich received his B.S. in biology from Amherst College and his M.S. in biomedical engineering from the University of Michigan. He holds an M.D. from Wayne State University and an M.B.A. from the Stanford University Graduate School of Business.
Mr. Lloyd-Smith joins Cadence from Elan Pharmaceuticals, Inc., where he was most recently Vice President and Head of Global Regulatory Affairs, and where he led the successful filings and approvals of Tysabri (natalizumab) and Prialt (ziconotide) in the United States and Europe. At Elan, he was responsible for the development and implementation of global regulatory strategy for all research and development and commercialization activities, as well as the global management of the pharmacovigilance and medical writing functions. Previously, Mr. Lloyd-Smith held senior regulatory positions with Bristol-Myers Squibb Pharmaceuticals and its predecessor, DuPont Pharmaceuticals, where he was most recently Vice President, Worldwide Regulatory Affairs. He received his M.S. in pharmacological biochemistry from Hatfield Polytechnic and his B.S. in pharmacology from the University of Leeds.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com/. |
| Tech People On the Move - California |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
SAN FRANCISCO--- FibroGen Appoints K. Peony Yu, M.D., Vice President, Clinical Development Posted 3:16 PM PST
SAN DIEGO--- NovaRx Appoints Industry Veteran as President and COO Posted 9:47 AM PST
SAN DIEGO--- Captura Group Names Renowned Hispanic Marketing Expert Felipe Korzenny, Ph.D. Senior Strategy Consultant Posted 9:22 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
SAN DIEGO--- DivX Announces Changes to Engineering Organization; Chief Technololgy Officer Resigns Posted 7:12 PM PST
MENLO PARK--- Caroline Loewy Joins Corcept as Chief Financial Officer Posted 7:32 AM PST
SAN FRANCISCO--- Neocase Software Appoints Julien Dahan Chief Executive Officer Posted 7:31 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
SACRAMENTO--- StrataScale Recruits Borland VP Robert Vincent to Be General Manager and CO Posted 8:42 AM PST
FOSTER CITY--- SciClone Pharmaceuticals Appoints Gary Titus as Chief Financial Officer Posted 8:28 AM PST
SAN DIEGO--- BrainCells Inc. Appoints David E. Thompson to Its Board of Directors Posted 8:23 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
AGOURA HILLS--- Symark International Appoints John Mutch as Chief Executive Officer Posted 8:32 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
